ELV Quantitative Stock Analysis

Validea's guru fundamental report rates Elevance Health Inc. (ELV) at 69% using the Martin Zweig Growth Investor model, which targets growth stocks with accelerating earnings and sales, reasonable valuations, and low debt. While ELV passed several key criteria such as P/E ratio and current quarter earnings growth, it failed on aspects like earnings persistence and long-term EPS growth, positioning it below the 80% threshold typically indicating strategic interest for this model.

Analysis

Validea's guru fundamental report assigns Elevance Health Inc. (ELV) a score of 69% using the Martin Zweig Growth Investor model, which prioritizes growth stocks exhibiting persistent accelerating earnings and sales, reasonable valuations, and low debt. This score falls below the 80% threshold typically indicating strategic interest for the model, suggesting a cautious stance despite ELV being a large-cap growth stock in the Insurance (Accident & Health) industry. The overall sentiment surrounding this report is mixed, with a low market impact score, reinforcing a neutral analytical perspective.

ELV demonstrated strength in several key areas, passing criteria such as its P/E ratio, revenue growth in relation to EPS growth, sales growth rate, and current quarter earnings performance. The company also passed on insider transactions, which can signal management confidence and alignment with shareholder interests.

However, the stock exhibited notable weaknesses in earnings consistency and long-term growth metrics, failing tests for earnings growth rate over several quarters, EPS growth for the current quarter relative to prior periods and historical rates, earnings persistence, and long-term EPS growth. These failures highlight potential concerns regarding the sustainability and predictability of its growth trajectory, which are critical components of the Zweig strategy.

The mixed results, particularly the failures in earnings persistence and long-term growth, contribute to the model's sub-threshold rating. This indicates that while some fundamental aspects are sound, ELV does not fully align with the aggressive, consistent growth criteria of the Martin Zweig strategy.

Key Decisions for Investors

• Investors considering ELV based on growth strategies should note its sub-optimal score of 69% under the Martin Zweig model, indicating it does not meet the full criteria for strong interest.
• Focus on the identified weaknesses in earnings persistence and long-term EPS growth, which suggest potential inconsistencies in its growth profile and may warrant closer scrutiny.
• Further due diligence is warranted to understand the drivers behind the inconsistent earnings growth and to assess if current valuation adequately reflects these growth challenges before making investment decisions.